Search

Your search keyword '"Fomina, D."' showing total 112 results
Start Over Author "Fomina, D." Publication Year Range Last 10 years
112 results on '"Fomina, D."'

10. Barriers of use of patient-reported outcome measures (PROMs) in asthma and rhinitis care: preliminary insights from the multinational ‘PROMUSE’ study

Author

Cherrez-Ojeda, I, primary, Bousquet, J, additional, Maurer, M, additional, Zuberbier, T, additional, Intriago, B, additional, Ramón, G D, additional, Larenas-Linnemann, D, additional, Caballero-López, C, additional, Al-Nesf Al-Mansouri, M, additional, Mohmmed Ibrahim, T, additional, Neisinger, S, additional, Fomina, D, additional, Zalewska, A, additional, Öztaş, R, additional, Mihaltan, F, additional, Kasperska-Zając, A, additional, Kolkhir, P, additional, Criado, R F, additional, Ensina, L F, additional, Chong Neto, H J, additional, Rosario, N, additional, Giménez-Arnau, A, additional, Pesqué, D, additional, Crespo Shijin, C, additional, Hinostroza Logroño, R, additional, and Robles-Velasco, K, additional

Published
2022
Full Text
View/download PDF

11. Physicians' preferences in the use of PROMs during asthma and allergic rhinitis clinical approach

Author

Bousquet, J, primary, Zuberbier, T, additional, Maurer, M, additional, Robles-Velasco, K, additional, Intriago, B, additional, Farfán Bajaña, M J, additional, Panchana Lascano, M, additional, Ramón, G D, additional, Krasowska, D, additional, Kolkhir, P, additional, Teovska, N, additional, Kasperska-Zajac, A, additional, Zalewska-Janowska, A, additional, Al-Ahmad, M, additional, Ali Al-Nesf, M, additional, Sabah, T, additional, Neisinger, S, additional, Mihaltan, F, additional, Khoshkhui, M, additional, Rukhadze, M, additional, Godse, K, additional, Giménez-Arnau, A M, additional, Pesqué, D, additional, Lingnau, A, additional, Christoff, G, additional, Popov, T, additional, Rodriguez, M, additional, Larenas Linnemann, D, additional, Fomina, D, additional, Kosnik, M, additional, Öztaş Kara, R, additional, Ivancevich, J C, additional, Rosario, N, additional, Ensina, L F, additional, Jardim Criado, R F, additional, Chong, H, additional, Caballero López, C G, additional, and Cherrez-Ojeda, I, additional

Published
2022
Full Text
View/download PDF

13. Federal guidelines on diagnosis and treatment of bronchial asthma

Author

Chuchalin, A. G., primary, Avdeev, S. N., additional, Aisanov, Z. R., additional, Belevskiy, A. S., additional, Vasil’eva, O. S., additional, Geppe, N. A., additional, Ignatova, G. L., additional, Knyazheskaya, N. P., additional, Malakhov, A. B., additional, Meshcheryakova, N. I., additional, Nenasheva, N. M., additional, Fassakhov, R. S., additional, Khaitov, R. M., additional, Il’ina, N. I., additional, Kurbacheva, O. M., additional, Astafieva, N. G., additional, Demko, I. V., additional, Fomina, D. S., additional, Namazova-Baranova, L. S., additional, Baranov, A. A., additional, Vishneva, E. A., additional, and Novik, G. A., additional

Published
2022
Full Text
View/download PDF

14. Adrenaline autoinjector is underprescribed in typical cold urticaria patients

Author

Bizjak, M. Košnik, M. Dinevski, D. Thomsen, S.F. Fomina, D. Borzova, E. Kulthanan, K. Meshkova, R. Aarestrup, F.M. Ahsan, D.M. Al-Ahmad, M. Altrichter, S. Bauer, A. Brockstädt, M. Costa, C. Demir, S. Criado, R.F. Ensina, L.F. Gelincik, A. Giménez-Arnau, A.M. Gonçalo, M. Gotua, M. Holm, J.G. Inomata, N. Kasperska-Zajac, A. Khoshkhui, M. Klyucharova, A. Kocatürk, E. Lu, R. Makris, M. Maltseva, N. Pasali, M. Paulino, M. Pesqué, D. Peter, J. Ramón, G.D. Ritchie, C. Rodrigues Valle, S.O. Rudenko, M. Sikora, A. Wagner, N. Xepapadaki, P. Xue, X. Zhao, Z. Terhorst-Molawi, D. Maurer, M.

Published
2022

15. Risk factors for systemic reactions in typical cold urticaria: Results from the COLD-CE study

Author

Bizjak, M. Košnik, M. Dinevski, D. Thomsen, S.F. Fomina, D. Borzova, E. Kulthanan, K. Meshkova, R. Ahsan, D.M. Al-Ahmad, M. Altrichter, S. Bauer, A. Brockstädt, M. Costa, C. Demir, S. Fachini Criado, R. Ensina, L.F. Gelincik, A. Giménez-Arnau, A.M. Gonçalo, M. Gotua, M. Holm, J.G. Inomata, N. Kasperska-Zajac, A. Khoshkhui, M. Klyucharova, A. Kocatürk, E. Lu, R. Makris, M. Maltseva, N. Miljković, J. Pasali, M. Paulino, M. Pesqué, D. Peter, J. Ramón, G.D. Ritchie, C. Rodrigues Valle, S.O. Rudenko, M. Sikora, A. de Souza Lima, E.M. Wagner, N. Xepapadaki, P. Xue, X. Zhao, Z. Terhorst-Molawi, D. Maurer, M.

Abstract

Background: Cold urticaria (ColdU), that is, the occurrence of wheals or angioedema in response to cold exposure, is classified into typical and atypical forms. The diagnosis of typical ColdU relies on whealing in response to local cold stimulation testing (CST). It can also manifest with cold-induced anaphylaxis (ColdA). We aimed to determine risk factors for ColdA in typical ColdU. Methods: An international, cross-sectional study COLD-CE was carried out at 32 urticaria centers of reference and excellence (UCAREs). Detailed history was taken and CST with an ice cube and/or TempTest® performed. ColdA was defined as an acute cold-induced involvement of the skin and/or visible mucosal tissue and at least one of: cardiovascular manifestations, difficulty breathing, or gastrointestinal symptoms. Results: Of 551 ColdU patients, 75% (n = 412) had a positive CST and ColdA occurred in 37% (n = 151) of the latter. Cold-induced generalized wheals, angioedema, acral swelling, oropharyngeal/laryngeal symptoms, and itch of earlobes were identified as signs/symptoms of severe disease. ColdA was most commonly provoked by complete cold water immersion and ColdA caused by cold air was more common in countries with a warmer climate. Ten percent (n = 40) of typical ColdU patients had a concomitant chronic spontaneous urticaria (CSU). They had a lower frequency of ColdA than those without CSU (4% vs. 39%, p =.003). We identified the following risk factors for cardiovascular manifestations: previous systemic reaction to a Hymenoptera sting, angioedema, oropharyngeal/laryngeal symptoms, and itchy earlobes. Conclusion: ColdA is common in typical ColdU. High-risk patients require education about their condition and how to use an adrenaline autoinjector. © 2021 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Published
2021

16. Additional file 1 of Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study

Author

Stanevich, O. V., Fomina, D. S., Bakulin, I. G., Galeev, S. I., Bakin, E. A., Belash, V. A., Kulikov, A. N., Lebedeva, A. A., Lioznov, D. A., Polushin, Yu. S., Shlyk, I. V., Vorobyev, E. A., Vorobyeva, S. V., Surovceva, T. V., Bakulina, N. V., Lysenko, M. A., and Moiseev, I. S.

Abstract

Additional file 1. Additional Figures S1���S8 and Tables S1���S7.

Published
2021
Full Text
View/download PDF

17. Autoimmune Chronic Spontaneous Urticaria Detection with IgG Anti-TPO and Total IgE

Author

Kolkhir, P., Kovalkova, E., Chernov, A., Danilycheva, I., Krause, K., Sauer, M., Shulzhenko, A., Fomina, D., Maurer, M., and Publica

Abstract

Background: Autoimmune chronic spontaneous urticaria (aiCSU) comes with high disease activity and poor response to treatment. Recently, elevated levels of IgG anti-thyroid peroxidase (aTPO) and low levels of total IgE were reported to be common in aiCSU. Objective: To investigate how high aTPO and low IgE individually and combined are linked to features of aiCSU, including treatment responses. Methods: We analyzed records of patients with CSU from 2 independent cohorts (n = 1120) for demographic, clinical, and laboratory parameters and treatment responses. Total IgE and aTPO were measured, and 4 markers of aiCSU were analyzed: autologous serum skin test, basophil activation test (BAT), and blood eosinophil and basophil counts. Cutoff values were greater than or equal to 34 kU/L (high aTPO) and less than 40 IU/mL (low total IgE). Results: One of 10 patients with CSU had both high aTPO and low IgE (aTPOUPIgEDN, 11%, n = 123). aTPOUPIgEDN was linked to higher age at CSU onset, being female, angioedema, and shorter CSU duration. aTPOUPIgEDN was associated with markers of aiCSU, that is, BAT and autologous serum skin test positivity, basopenia, and eosinopenia (P < .01 for all). Almost half the patients with aTPOUPIgEDN (44%, 19 of 43) had a positive BAT result, the best single marker for aiCSU, versus 12% (43 of 344) of patients without aTPOUPIgEDN (P < .001). Relative risk of showing BAT positivity for a patient with aTPOUPIgEDN is 3.636 (95% CI, 2.382-5.551). Patients with aTPOUPIgEDN showed low response rates to antihistamine treatment as compared with patients without aTPOUPIgEDN (30% vs 47%; P = .01). Conclusions: Our findings suggest that aTPOUPIgEDN is a useful diagnostic marker for aiCSU in everyday clinical practice.

Published
2021

19. POS1214 THE DYNAMICS OF INFLAMMATORY MARKERS IN COVID-19 PATIENTS TREATED WITH LEVILIMAB

Author

Lomakin, N., primary, Bakirov, B., additional, Musaev, G., additional, Protsenko, D., additional, Moiseeva, O., additional, Pasechnik, E., additional, Popov, V., additional, Smolyarchuk, E., additional, Gordeev, I., additional, Gilyarov, M., additional, Fomina, D., additional, Mazurov, V., additional, Morozova, M., additional, Dokukina, E., additional, Bogdan, D., additional, Lutskii, A., additional, Zinkina-Orihan, A., additional, Linkova, I., additional, and Seleznev, A., additional

Published
2021
Full Text
View/download PDF

20. Baricitinib in the Treatment of Patients with COVID-19: A Review of International Data and Analysis of Clinical Results in the Russian Population

Author

Zagrebneva, А. I., primary, Baryakh, Е. А., additional, Zhelnova, Е. I., additional, Poteshkina, N. G., additional, Beloglazova, I. Р., additional, Mutovina, Z. Yu., additional, Samsonova, I. V., additional, Kovalevskaya, Е. А., additional, Parshin, V. V., additional, Pshenichnikova, V. V., additional, Fomina, D S., additional, Kruglova, Т. S., additional, Lysenko, М. А., additional, and Dranitsyna, М. А., additional

Published
2021
Full Text
View/download PDF

21. How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? a UCARE study

Author

Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Cherrez-Ojeda, I.; Vanegas, E.; Cherrez, A.; Felix, M.; Weller, K.; Magerl, M.; Maurer, R. R.; Mata, V. L.; Kasperska-Zajac, A.; Sikora, A.; Fomina, D.; Kovalkova, E.; Godse, K.; Rao, N. D.; Khoshkhui, M.; Rastgoo, S.; Criado, R. F.; Abuzakouk, M.; Grandon, D.; Van Doorn, M. B. A.; Oliveira Rodrigues Valle, S.; De Souza Lima, E. M.; Thomsen, S. F.; Ramón, G. D.; Matos Benavides, E. E.; Bauer, A.; Giménez-Arnau, A. M.; Guillet, C.; Larco, J. I.; Zhao, Z.- T.; Makris, M.; Ritchie, C.; Xepapadaki, P.; Ensina, L. F.; Cherrez, S.; Maurer, M., Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), and Cherrez-Ojeda, I.; Vanegas, E.; Cherrez, A.; Felix, M.; Weller, K.; Magerl, M.; Maurer, R. R.; Mata, V. L.; Kasperska-Zajac, A.; Sikora, A.; Fomina, D.; Kovalkova, E.; Godse, K.; Rao, N. D.; Khoshkhui, M.; Rastgoo, S.; Criado, R. F.; Abuzakouk, M.; Grandon, D.; Van Doorn, M. B. A.; Oliveira Rodrigues Valle, S.; De Souza Lima, E. M.; Thomsen, S. F.; Ramón, G. D.; Matos Benavides, E. E.; Bauer, A.; Giménez-Arnau, A. M.; Guillet, C.; Larco, J. I.; Zhao, Z.- T.; Makris, M.; Ritchie, C.; Xepapadaki, P.; Ensina, L. F.; Cherrez, S.; Maurer, M.

Abstract

Background: patients with chronic urticaria (CU) are increasingly using information and communication technologies (ICTs) to manage their health. What CU patients expect from ICTs and which ICTs they prefer remains unknown. We assessed why CU patients use ICTs, which ones they prefer, and what drives their expectations and choices. Methods: in this cross-sectional study, 1841 patients across 17 countries were recruited at UCAREs (Urticaria Centers of Reference and Excellence). Patients with CU who were >12 years old completed a 23-item questionnaire. Results: most patients were interested in receiving disease information (87.3%), asking physicians about CU (84.1%), and communicating with other patients through ICTs (65.6%). For receiving disease information, patients preferred one-to-one and one-to-many ICTs, especially web browsers. One-to-one ICTs were also the ICTs of choice for asking physicians about urticaria and for communicating with other patients, and e-mail and WhatsApp were the preferred ICTs, respectively. Many-to-many ICTs such as Facebook, Instagram, LinkedIn, and Twitter were least preferred for all 3 purposes. Living in rural areas and higher education were linked to higher odds of being interested in receiving disease information, asking physicians, and communicating with patients through ICTs. Conclusions: most patients and especially patients with higher education who live in rural areas are interested in using ICTs for their healthcare, but prefer different ICTs for different purposes, ie, web browsers for obtaining information, e-mail for asking physicians, and WhatsApp for communicating with other patients. Our findings may help to improve ICTs for CU.

Published
2021

23. The global burden of chronic urticaria for the patient and society*

Author

Gonçalo, M., primary, Gimenéz‐Arnau, A., additional, Al‐Ahmad, M., additional, Ben‐Shoshan, M., additional, Bernstein, J.A., additional, Ensina, L.F., additional, Fomina, D., additional, Galvàn, C.A., additional, Godse, K., additional, Grattan, C., additional, Hide, M., additional, Katelaris, C.H., additional, Khoshkhui, M., additional, Kocatürk, E., additional, Kulthanan, K., additional, Medina, I., additional, Nasr, I., additional, Peter, J., additional, Staubach, P., additional, Wang, L., additional, Weller, K., additional, and Maurer, M., additional

Published
2020
Full Text
View/download PDF

25. Comparative analysis of tocilizumab in severe COVID-19-associated pneumonia in patients of different age groups

Author

Fomina, D. S., primary, Poteshkina, N. G., additional, Beloglazova, I. P., additional, Mutovina, Z. Yu., additional, Samsonova, I. V., additional, Kovalevskaya, E. A., additional, Zagrebneva, A. I., additional, Frolova, N. F., additional, Krlikova, D. S., additional, Kruglova, T. S., additional, Bobrikova, E. N., additional, Serdotetskova, S. A., additional, Manchenko, O. V., additional, Markova, T. N., additional, Chernov, A. A., additional, and Lysenko, M. A., additional

Published
2020
Full Text
View/download PDF

27. Museum Virtualization: Opportunities and Risks

Author

Fomina, D. D. and Pankina, M. V.

Subjects
CULTURE, DESIGN, МУЗЕЙ, VIRTUALIZATION, CULTURAL AND COMMUNICATION SPACE, КУЛЬТУРНО-КОММУНИКАТИВНОЕ ПРОСТРАНСТВО, MUSEUM, ДИЗАЙН, КУЛЬТУРА, ВИРТУАЛИЗАЦИЯ
Abstract

В статье рассматривается процесс трансформации музеев как средства трансляции культурных ценностей. Авторы анализируют влияние информационно-телекоммуникационных технологий и дизайна на культурно-коммуникативную среду музея, выявляют современные тенденции. Среди основных направлений выделяется наиболее развивающееся — виртуализация музеев. Исследуются противоречивые аспекты этого явления. The article considers the process of transformation of museums as a means of broadcasting cultural values. The authors analyze the impact of information and telecommunications technologies and design on the cultural and communicative environment of the museum, identify current trends in the development of Museum business. Among the main directions of the most rapidly expanding virtualization of museums. Contradictory aspects of this phenomenon are investigated.

Published
2020

28. The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study

Author

Maurer, M. Weller, K. Magerl, M. Maurer, R.R. Vanegas, E. Felix, M. Cherrez, A. Mata, V.L. Kasperska-Zajac, A. Sikora, A. Fomina, D. Kovalkova, E. Godse, K. Rao, N.D. Khoshkhui, M. Rastgoo, S. Criado, R.F.J. Abuzakouk, M. Grandon, D. van Doorn, M. Valle, S.O.R. de Souza Lima, E.M. Thomsen, S.F. Ramón, G.D. Matos Benavides, E.E. Bauer, A. Giménez-Arnau, A.M. Kocatürk, E. Guillet, C. Ignacio Larco, J. Zhao, Z.-T. Makris, M. Ritchie, C. Xepapadaki, P. Ensina, L.F. Cherrez, S. Cherrez-Ojeda, I.

Abstract

Background: Chronic urticaria (CU) is characterized by itchy recurrent wheals, angioedema, or both for 6 weeks or longer. CU can greatly impact patients' physical and emotional quality of life. Patients with chronic conditions are increasingly seeking information from information and communications technologies (ICTs) to manage their health. The objective of this study was to assess the frequency of usage and preference of ICTs from the perspective of patients with CU. Methods: In this cross-sectional study, 1800 patients were recruited from primary healthcare centers, university hospitals or specialized clinics that form part of the UCARE (Urticaria Centers of Reference and Excellence) network throughout 16 countries. Patients were >12 years old and had physician-diagnosed chronic spontaneous urticaria (CSU) or chronic inducible urticaria (CIndU). Patients completed a 23-item questionnaire containing questions about ICT usage, including the type, frequency, preference, and quality, answers to which were recorded in a standardized database at each center. For analysis, ICTs were categorized into 3 groups as follows: one-to-one: SMS, WhatsApp, Skype, and email; one-to-many: YouTube, web browsers, and blogs or forums; many-to-many: Instagram, Twitter, Facebook, and LinkedIn. Results: Overall, 99.6% of CU patients had access to ICT platforms and 96.7% had internet access. Daily, 85.4% patients used one-to-one ICT platforms most often, followed by one-to-many ICTs (75.5%) and many-to-many ICTs (59.2%). The daily ICT usage was highest for web browsers (72.7%) and WhatsApp (70.0%). The general usage of ICT platforms increased in patients with higher levels of education. One-to-many was the preferred ICT category for obtaining general health information (78.3%) and for CU-related information (75.4%). A web browser (77.6%) was by far the most commonly used ICT to obtain general health information, followed by YouTube (25.8%) and Facebook (16.3%). Similarly, for CU-specific information, 3 out of 4 patients (74.6%) used a web browser, 20.9% used YouTube, and 13.6% used Facebook. One in 5 (21.6%) patients did not use any form of ICT for obtaining information on CU. The quality of the information obtained from one-to-many ICTs was rated much more often as very interesting and of good quality for general health information (53.5%) and CU-related information (51.5%) as compared to the other categories. Conclusions: Usage of ICTs for health and CU-specific information is extremely high in all countries analyzed, with web browsers being the preferred ICT platform. © 2020

Published
2020

29. Toward personalization of asthma treatment according to trigger factors

Author

Niespodziana, K. Borochova, K. Pazderova, P. Schlederer, T. Astafyeva, N. Baranovskaya, T. Barbouche, M.-R. Beltyukov, E. Berger, A. Borzova, E. Bousquet, J. Bumbacea, R.S. Bychkovskaya, S. Caraballo, L. Chung, K.F. Custovic, A. Docena, G. Eiwegger, T. Evsegneeva, I. Emelyanov, A. Errhalt, P. Fassakhov, R. Fayzullina, R. Fedenko, E. Fomina, D. Gao, Z. Giavina-Bianchi, P. Gotua, M. Greber-Platzer, S. Hedlin, G. Ilina, N. Ispayeva, Z. Idzko, M. Johnston, S.L. Kalayci, Ö. Karaulov, A. Karsonova, A. Khaitov, M. Kovzel, E. Kowalski, M.L. Kudlay, D. Levin, M. Makarova, S. Matricardi, P.M. Nadeau, K.C. Namazova-Baranova, L. Naumova, O. Nazarenko, O. O'Byrne, P.M. Osier, F. Pampura, A.N. Panaitescu, C. Papadopoulos, N.G. Park, H.-S. Pawankar, R. Pohl, W. Renz, H. Riabova, K. Sampath, V. Sekerel, B.E. Sibanda, E. Siroux, V. Sizyakina, L.P. Sun, J.-L. Szepfalusi, Z. Umanets, T. Van Bever, H.P.S. van Hage, M. Vasileva, M. von Mutius, E. Wang, J.-Y. Wong, G.W.K. Zaikov, S. Zidarn, M. Valenta, R.

Subjects
immune system diseases, respiratory tract diseases
Abstract

Asthma is a severe and chronic disabling disease affecting more than 300 million people worldwide. Although in the past few drugs for the treatment of asthma were available, new treatment options are currently emerging, which appear to be highly effective in certain subgroups of patients. Accordingly, there is a need for biomarkers that allow selection of patients for refined and personalized treatment strategies. Recently, serological chip tests based on microarrayed allergen molecules and peptides derived from the most common rhinovirus strains have been developed, which may discriminate 2 of the most common forms of asthma, that is, allergen- and virus-triggered asthma. In this perspective, we argue that classification of patients with asthma according to these common trigger factors may open new possibilities for personalized management of asthma. © 2020 The Authors

Published
2020

30. Виртуализация музеев: возможности и риски

Author

Fomina, D. D., Pankina, M. V., Фомина, Д. Д., Панкина, М. В., Fomina, D. D., Pankina, M. V., Фомина, Д. Д., and Панкина, М. В.

Abstract

В статье рассматривается процесс трансформации музеев как средства трансляции культурных ценностей. Авторы анализируют влияние информационно-телекоммуникационных технологий и дизайна на культурно-коммуникативную среду музея, выявляют современные тенденции. Среди основных направлений выделяется наиболее развивающееся — виртуализация музеев. Исследуются противоречивые аспекты этого явления., The article considers the process of transformation of museums as a means of broadcasting cultural values. The authors analyze the impact of information and telecommunications technologies and design on the cultural and communicative environment of the museum, identify current trends in the development of Museum business. Among the main directions of the most rapidly expanding virtualization of museums. Contradictory aspects of this phenomenon are investigated.

Published
2020

31. The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study

Author

Maurer, M., Weller, K., Magerl, M., Maurer, R.R., Vanegas, E., Felix, M., Cherrez, A., Mata, V.L., Kasperska-Zajac, A., Sikora, A., Fomina, D., Kovalkova, E., Godse, K., Rao, N.D., Khoshkhui, M., Rastgoo, S., Criado, R.F.J., Abuzakouk, M., Grandon, D., van Doorn, M., Valle, S.O.R., de Souza Lima, E.M., Thomsen, S.F., Ramón, G.D., Matos Benavides, E.E., Bauer, A., Giménez-Arnau, A.M., Kocatürk, E., Guillet, C., Ignacio Larco, J., Zhao, Z.T., Makris, M. (M.), Ritchie, C, Xepapadaki, P., Ensina, L.F., Cherrez, S., Cherrez-Ojeda, I., Maurer, M., Weller, K., Magerl, M., Maurer, R.R., Vanegas, E., Felix, M., Cherrez, A., Mata, V.L., Kasperska-Zajac, A., Sikora, A., Fomina, D., Kovalkova, E., Godse, K., Rao, N.D., Khoshkhui, M., Rastgoo, S., Criado, R.F.J., Abuzakouk, M., Grandon, D., van Doorn, M., Valle, S.O.R., de Souza Lima, E.M., Thomsen, S.F., Ramón, G.D., Matos Benavides, E.E., Bauer, A., Giménez-Arnau, A.M., Kocatürk, E., Guillet, C., Ignacio Larco, J., Zhao, Z.T., Makris, M. (M.), Ritchie, C, Xepapadaki, P., Ensina, L.F., Cherrez, S., and Cherrez-Ojeda, I.

Abstract

Background: Chronic urticaria (CU) is characterized by itchy recurrent wheals, angioedema, or both for 6 weeks or longer. CU can greatly impact patients' physical and emotional quality of life. Patients with chronic conditions are increasingly seeking information from information and communications technologies (ICTs) to manage their health. The objective of this study was to assess the frequency of usage and preference of ICTs from the perspective of patients with CU. Methods: In this cross-sectional study, 1800 patients were recruited from primary healthcare centers, university hospitals or specialized clinics that form part of the UCARE (Urticaria Centers of Reference and Excellence) network throughout 16 countries. Patients were >12 years old and had physician-diagnosed chronic spontaneous urticaria (CSU) or chronic inducible urticaria (CIndU). Patients completed a 23-item questionnaire containing questions about ICT usage, including the type, frequency, preference, and quality, answers to which were recorded in a standardized database at each center. For analysis, ICTs were categorized into 3 groups as follows: one-to-one: SMS, WhatsApp, Skype, and email; one-to-many: YouTube, web browsers, and blogs or forums; many-to-many: Instagram, Twitter, Facebook, and LinkedIn. Results: Overall, 99.6% of CU patients had access to ICT platforms and 96.7% had internet access. Daily, 85.4% patients used one-to-one ICT platforms most often, followed by one-to-many ICTs (75.5%) and many-to-many ICTs (59.2%). The daily ICT usage was highest for web browsers (72.7%) and WhatsApp (70.0%). The general usage of ICT platforms increased in patients with higher levels of education. One-to-many was the preferred ICT category for obtaining general health information (7

Published
2020
Full Text
View/download PDF

32. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria

Author

Kocatürk, E., Salman, A. (Andaç), Cherrez-Ojeda, I. (Ivan), Ricardo Criado, P. (Paulo), Peter, J. (Jonny), Comert-Ozer, E. (Elif), Abuzakouk, M. (M.), Câmara Agondi, R. (Rosana), Al-Ahmad, M. (Mona), Altrichter, S. (Sabine), Arnaout, R. (Rand), Arruda, L.K. (Luisa Karla), Asero, R. (Riccardo), Bauer, A. (Andrea), Ben-Shoshan, M. (Moshe), Bernstein, J.A. (Jonathan A.), Bizjak, M. (Mojca), Boccon-Gibod, I. (Isabelle), Bonnekoh, H. (Hanna), Bouillet, L. (Laurence), Brzoza, Z. (Zenon), Busse, P. (Paula), Campos, R.A. (Regis A), Carne, E. (Emily), Conlon, N. (Niall), Criado, R.F. (Roberta F.), de Souza Lima, E.M. (Eduardo M.), Demir, S. (Semra), Dissemond, J. (Joachim), Doğan Günaydın, S. (Sibel), Dorofeeva, I. (Irina), Felipe Ensina, L. (Luis), Ertaş, R. (Ragıp), Mariel Ferrucci, S. (Silvia), Figueras-Nart, I. (Ignasi), Fomina, D. (Daria), Franken, S.M. (Sylvie M), Fukunaga, A. (Atsushi), Giménez-Arnau, A., Godse, K., Gonçalo, M. (Margarida), Gotua, M. (M.), Grattan, C., Guillet, C. (Carole), Inomata, N. (Naoko), Jakob, T. (Thilo), Karakaya, G. (Gul), Kasperska-Zając, A. (Alicja), Katelaris, C.H. (Constance H), Košnik, M. (Mitja), Krasowska, D. (Dorota), Kulthanan, K. (Kanokvalai), Sendhil Kumaran, M. (M.), Lang, C. (Claudia), Ignacio Larco-Sousa, J. (José), Lazaridou, E. (Elisavet), Anika Leslie, T. (Tabi), Lippert, U. (Undine), Calderón llosa, O. (Oscar), Makris, M. (Michael), Marsland, A. (Alexander), Medina, I.V. (Iris V.), Meshkova, R. (Raisa), Bastos Palitot, E. (Esther), Parisi, C.A.S. (Claudio A.S.), Pickert, J. (Julia), Ramon, G.D. (German D.), Rodríguez-Gonzalez, M. (Mónica), Rosario, N. (Nelson), Rudenko, M. (Michael), Rutkowski, K. (Krzysztof), Sánchez, J. (Jorge), Schliemann, S. (Sibylle), Sekerel, B.E. (Bulent Enis), Serpa, F.S. (Faradiba S.), Serra-Baldrich, E. (Esther), Song, Z. (Zhiqiang), Soria, A. (Angèle), Staevska, M. (Maria), Staubach, P. (Petra), Tagka, A. (Anna), Takahagi, S. (Shunsuke), Thomsen, S.F. (Simon Francis), Treudler, R. (Regina), Vadasz, Z. (Zahava), Oliveira Rodrigues Valle, S. (Solange), Doorn, M.B.A. (Martijn) van, Vestergaard, C. (C.), Wagner, N. (Nicola), Wang, D. (Dahu), Wang, L. (Liangchun), Wedi, B. (Bettina), Xepapadaki, P. (Paraskevi), Yücel, E. (Esra), Zalewska-Janowska, A. (Anna), Zhao, Z. (Zuotao), Zuberbier, T. (Torsten), Maurer, M. (Marcus), Kocatürk, E., Salman, A. (Andaç), Cherrez-Ojeda, I. (Ivan), Ricardo Criado, P. (Paulo), Peter, J. (Jonny), Comert-Ozer, E. (Elif), Abuzakouk, M. (M.), Câmara Agondi, R. (Rosana), Al-Ahmad, M. (Mona), Altrichter, S. (Sabine), Arnaout, R. (Rand), Arruda, L.K. (Luisa Karla), Asero, R. (Riccardo), Bauer, A. (Andrea), Ben-Shoshan, M. (Moshe), Bernstein, J.A. (Jonathan A.), Bizjak, M. (Mojca), Boccon-Gibod, I. (Isabelle), Bonnekoh, H. (Hanna), Bouillet, L. (Laurence), Brzoza, Z. (Zenon), Busse, P. (Paula), Campos, R.A. (Regis A), Carne, E. (Emily), Conlon, N. (Niall), Criado, R.F. (Roberta F.), de Souza Lima, E.M. (Eduardo M.), Demir, S. (Semra), Dissemond, J. (Joachim), Doğan Günaydın, S. (Sibel), Dorofeeva, I. (Irina), Felipe Ensina, L. (Luis), Ertaş, R. (Ragıp), Mariel Ferrucci, S. (Silvia), Figueras-Nart, I. (Ignasi), Fomina, D. (Daria), Franken, S.M. (Sylvie M), Fukunaga, A. (Atsushi), Giménez-Arnau, A., Godse, K., Gonçalo, M. (Margarida), Gotua, M. (M.), Grattan, C., Guillet, C. (Carole), Inomata, N. (Naoko), Jakob, T. (Thilo), Karakaya, G. (Gul), Kasperska-Zając, A. (Alicja), Katelaris, C.H. (Constance H), Košnik, M. (Mitja), Krasowska, D. (Dorota), Kulthanan, K. (Kanokvalai), Sendhil Kumaran, M. (M.), Lang, C. (Claudia), Ignacio Larco-Sousa, J. (José), Lazaridou, E. (Elisavet), Anika Leslie, T. (Tabi), Lippert, U. (Undine), Calderón llosa, O. (Oscar), Makris, M. (Michael), Marsland, A. (Alexander), Medina, I.V. (Iris V.), Meshkova, R. (Raisa), Bastos Palitot, E. (Esther), Parisi, C.A.S. (Claudio A.S.), Pickert, J. (Julia), Ramon, G.D. (German D.), Rodríguez-Gonzalez, M. (Mónica), Rosario, N. (Nelson), Rudenko, M. (Michael), Rutkowski, K. (Krzysztof), Sánchez, J. (Jorge), Schliemann, S. (Sibylle), Sekerel, B.E. (Bulent Enis), Serpa, F.S. (Faradiba S.), Serra-Baldrich, E. (Esther), Song, Z. (Zhiqiang), Soria, A. (Angèle), Staevska, M. (Maria), Staubach, P. (Petra), Tagka, A. (Anna), Takahagi, S. (Shunsuke), Thomsen, S.F. (Simon Francis), Treudler, R. (Regina), Vadasz, Z. (Zahava), Oliveira Rodrigues Valle, S. (Solange), Doorn, M.B.A. (Martijn) van, Vestergaard, C. (C.), Wagner, N. (Nicola), Wang, D. (Dahu), Wang, L. (Liangchun), Wedi, B. (Bettina), Xepapadaki, P. (Paraskevi), Yücel, E. (Esra), Zalewska-Janowska, A. (Anna), Zhao, Z. (Zuotao), Zuberbier, T. (Torsten), and Maurer, M. (Marcus)

Abstract

Introduction: The COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: To understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and Methods: Our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results: The COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three pat

Published
2020
Full Text
View/download PDF

33. Definition, aims, and implementation of GA2LEN/HAEi Angioedema Centers of Reference and Excellence

Author

Maurer, M. (Marcus), Aberer, W. (W.), Agondi, R. (Rosana), Al-Ahmad, M. (Mona), Al-Nesf, M.A. (Maryam Ali), Ansotegui, I.J. (I.), Arnaout, R. (Rand), Arruda, L.K. (Luisa Karla), Asero, R. (Riccardo), Aygören-Pürsü, E. (Emel), Banerji, A. (Aleena), Bauer, A. (Andrea), Ben-Shoshan, M. (Moshe), Berardi, A. (Alejandro), Bernstein, J.A. (Jonathan A.), Betschel, S. (Stephen), Bindslev-Jensen, C. (Carsten), Bizjak, M. (Mojca), Boccon-Gibod, I. (Isabelle), Bork, K. (Konrad), Bouillet, L. (Laurence), Boysen, H.B. (Henrik Balle), Brodszki, N. (N.), Broesby-Olsen, S. (Sigurd), Busse, P. (Paula), Buttgereit, T. (Thomas), Bygum, A. (Anette), Caballero, T. (Teresa), Campos, R.A. (Régis A.), Cancian, M. (Mauro), Cherrez-Ojeda, I. (Ivan), Cohn, D.M. (Danny M.), Costa, C. (Célia), Craig, T., Criado, P.R. (Paulo Ricardo), Criado, R.F. (Roberta F.), Csuka, D. (Dorottya), Dissemond, J. (Joachim), Du-Thanh, A. (Aurélie), Ensina, L.F. (Luis Felipe), Ertaş, R. (Ragıp), Fabiani, J.E. (José E.), Fantini, C. (Claudio), Farkas, H. (Henriette), Ferrucci, S.M. (Silvia Mariel), Figueras-Nart, I. (Ignasi), Fili, N.L. (Natalia L.), Fomina, D. (Daria), Fukunaga, A. (Atsushi), Gelincik, A. (Asli), Giménez-Arnau, A., Godse, K., Gompels, M. (Mark), Gonçalo, M. (Margarida), Gotua, M. (M.), Gower, R. (Richard), Grumach, A.S. (Anete S.), Guidos-Fogelbach, G. (Guillermo), Hide, M. (Michihiro), Ilina, N. (Natalia), Inomata, N. (Naoko), Jakob, T. (Thilo), Josviack, D.O. (Dario O.), Kang, H.-R. (Hye-Ryun), Kaplan, A. (Allen), Kasperska-Zając, A. (Alicja), Katelaris, C. (Constance), Kessel, A. (Aharon), Kleinheinz, A. (Andreas), Kocatürk, E., Košnik, M. (Mitja), Krasowska, D. (Dorota), Kulthanan, K. (Kanokvalai), Kumaran, M.S. (M. Sendhil), Larco Sousa, J.I. (José Ignacio), Longhurst, H.J. (Hilary J.), Lumry, W. (William), MacGinnitie, A. (Andrew), Magerl, M. (Markus), Makris, M.P. (Michael P.), Malbrán, A. (Alejandro), Marsland, A. (Alexander), Martinez-Saguer, I. (Inmaculada), Medina, I.V. (Iris V.), Meshkova, R. (Raisa), Metz, M. (Martin), Nasr, I. (Iman), Nicolay, J. (Jan), Nishigori, C. (Chikako), Ohsawa, I. (Isao), Özyurt, K. (Kemal), Papadopoulos, N., Parisi, C.A.S. (Claudio A. S.), Peter, J.G. (Jonathan Grant), Pfützner, W. (W.), Popov, T.A., Prior, N. (Nieves), Ramon, G.D. (German D.), Reich, A. (Adam), Reshef, A. (Avner), Riedl, M.A. (Marc A.), Ritchie, B. (Bruce), Röckmann-Helmbach, H. (Heike), Rudenko, M. (Michael), Salman, A. (Andaç), Sanchez-Borges, M. (Mario), Schmid-Grendelmeier, P. (Peter), Serpa, F.S. (Faradiba S.), Serra-Baldrich, E. (Esther), Sheikh, F.R. (Farrukh R.), Smith, W. (William), Soria, A. (Angèle), Staubach, P. (Petra), Steiner, U.C. (Urs C.), Stobiecki, M. (Marcin), Sussman, G. (Gordon), Tagka, A. (Anna), Thomsen, S.F. (Simon Francis), Treudler, R. (Regina), Valle, S. (Solange), Doorn, M.B.A. (Martijn) van, Varga, L. (Lilian), Vázquez, D.O. (Daniel O.), Wagner, N. (Nicola), Wang, L. (Liangchun), Weber-Chrysochoou, C. (Christina), Ye, Y.-M. (Young-Min), Zalewska-Janowska, A. (Anna), Zanichelli, A. (Andrea), Zhao, Z. (Zuotao), Zhi, Y. (Yuxiang), Zuberbier, T. (Torsten), Zwiener, R.D. (Ricardo D.), Castaldo, A. (Anthony), Maurer, M. (Marcus), Aberer, W. (W.), Agondi, R. (Rosana), Al-Ahmad, M. (Mona), Al-Nesf, M.A. (Maryam Ali), Ansotegui, I.J. (I.), Arnaout, R. (Rand), Arruda, L.K. (Luisa Karla), Asero, R. (Riccardo), Aygören-Pürsü, E. (Emel), Banerji, A. (Aleena), Bauer, A. (Andrea), Ben-Shoshan, M. (Moshe), Berardi, A. (Alejandro), Bernstein, J.A. (Jonathan A.), Betschel, S. (Stephen), Bindslev-Jensen, C. (Carsten), Bizjak, M. (Mojca), Boccon-Gibod, I. (Isabelle), Bork, K. (Konrad), Bouillet, L. (Laurence), Boysen, H.B. (Henrik Balle), Brodszki, N. (N.), Broesby-Olsen, S. (Sigurd), Busse, P. (Paula), Buttgereit, T. (Thomas), Bygum, A. (Anette), Caballero, T. (Teresa), Campos, R.A. (Régis A.), Cancian, M. (Mauro), Cherrez-Ojeda, I. (Ivan), Cohn, D.M. (Danny M.), Costa, C. (Célia), Craig, T., Criado, P.R. (Paulo Ricardo), Criado, R.F. (Roberta F.), Csuka, D. (Dorottya), Dissemond, J. (Joachim), Du-Thanh, A. (Aurélie), Ensina, L.F. (Luis Felipe), Ertaş, R. (Ragıp), Fabiani, J.E. (José E.), Fantini, C. (Claudio), Farkas, H. (Henriette), Ferrucci, S.M. (Silvia Mariel), Figueras-Nart, I. (Ignasi), Fili, N.L. (Natalia L.), Fomina, D. (Daria), Fukunaga, A. (Atsushi), Gelincik, A. (Asli), Giménez-Arnau, A., Godse, K., Gompels, M. (Mark), Gonçalo, M. (Margarida), Gotua, M. (M.), Gower, R. (Richard), Grumach, A.S. (Anete S.), Guidos-Fogelbach, G. (Guillermo), Hide, M. (Michihiro), Ilina, N. (Natalia), Inomata, N. (Naoko), Jakob, T. (Thilo), Josviack, D.O. (Dario O.), Kang, H.-R. (Hye-Ryun), Kaplan, A. (Allen), Kasperska-Zając, A. (Alicja), Katelaris, C. (Constance), Kessel, A. (Aharon), Kleinheinz, A. (Andreas), Kocatürk, E., Košnik, M. (Mitja), Krasowska, D. (Dorota), Kulthanan, K. (Kanokvalai), Kumaran, M.S. (M. Sendhil), Larco Sousa, J.I. (José Ignacio), Longhurst, H.J. (Hilary J.), Lumry, W. (William), MacGinnitie, A. (Andrew), Magerl, M. (Markus), Makris, M.P. (Michael P.), Malbrán, A. (Alejandro), Marsland, A. (Alexander), Martinez-Saguer, I. (Inmaculada), Medina, I.V. (Iris V.), Meshkova, R. (Raisa), Metz, M. (Martin), Nasr, I. (Iman), Nicolay, J. (Jan), Nishigori, C. (Chikako), Ohsawa, I. (Isao), Özyurt, K. (Kemal), Papadopoulos, N., Parisi, C.A.S. (Claudio A. S.), Peter, J.G. (Jonathan Grant), Pfützner, W. (W.), Popov, T.A., Prior, N. (Nieves), Ramon, G.D. (German D.), Reich, A. (Adam), Reshef, A. (Avner), Riedl, M.A. (Marc A.), Ritchie, B. (Bruce), Röckmann-Helmbach, H. (Heike), Rudenko, M. (Michael), Salman, A. (Andaç), Sanchez-Borges, M. (Mario), Schmid-Grendelmeier, P. (Peter), Serpa, F.S. (Faradiba S.), Serra-Baldrich, E. (Esther), Sheikh, F.R. (Farrukh R.), Smith, W. (William), Soria, A. (Angèle), Staubach, P. (Petra), Steiner, U.C. (Urs C.), Stobiecki, M. (Marcin), Sussman, G. (Gordon), Tagka, A. (Anna), Thomsen, S.F. (Simon Francis), Treudler, R. (Regina), Valle, S. (Solange), Doorn, M.B.A. (Martijn) van, Varga, L. (Lilian), Vázquez, D.O. (Daniel O.), Wagner, N. (Nicola), Wang, L. (Liangchun), Weber-Chrysochoou, C. (Christina), Ye, Y.-M. (Young-Min), Zalewska-Janowska, A. (Anna), Zanichelli, A. (Andrea), Zhao, Z. (Zuotao), Zhi, Y. (Yuxiang), Zuberbier, T. (Torsten), Zwiener, R.D. (Ricardo D.), and Castaldo, A. (Anthony)

Published
2020
Full Text
View/download PDF

34. The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study

Author

Maurer, M, Weller, K, Magerl, M, Maurer, RR, Vanegas, E, Felix, M, Cherrez, A, Mata, VL, Kasperska-Zajac, A, Sikora, A, Fomina, D, Kovalkova, E, Godse, K, Rao, ND, Khoshkhui, M, Rastgoo, S, Criado, RFJ, Abuzakouk, M, Grandon, D, van Doorn, Martijn, Valle, SOR, de Souza Lima, EM, Thomsen, SF, Ramón, GD, Matos Benavides, EE, Bauer, A, Giménez-Arnau, AM, Kocatürk, E, Guillet, C, Ignacio Larco, J, Zhao, ZT, Makris, M, Ritchie, C, Xepapadaki, P, Ensina, LF, Cherrez, S, Cherrez-Ojeda, I, Maurer, M, Weller, K, Magerl, M, Maurer, RR, Vanegas, E, Felix, M, Cherrez, A, Mata, VL, Kasperska-Zajac, A, Sikora, A, Fomina, D, Kovalkova, E, Godse, K, Rao, ND, Khoshkhui, M, Rastgoo, S, Criado, RFJ, Abuzakouk, M, Grandon, D, van Doorn, Martijn, Valle, SOR, de Souza Lima, EM, Thomsen, SF, Ramón, GD, Matos Benavides, EE, Bauer, A, Giménez-Arnau, AM, Kocatürk, E, Guillet, C, Ignacio Larco, J, Zhao, ZT, Makris, M, Ritchie, C, Xepapadaki, P, Ensina, LF, Cherrez, S, and Cherrez-Ojeda, I

Published
2020

35. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria

Author

Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Salman, A.; Cherrez-Ojeda, I.; Criado, P. R.; Peter, J.; Comert-Ozer, E.; Abuzakouk, M.; Agondi, R. C.; Al-Ahmad, M.; Altrichter, S.; Arnaout, R.; Arruda, L. K.; Asero, R.; Bauer, A.; Ben-Shoshan, M.; Bernstein, J. A.; Bizjak, M.; Boccon-Gibod, I.; Bonnekoh, H.; Bouillet, L.; Brzoza, Z.; Busse, P.; Campos, R. A.; Carne, E.; Conlon, N.; Criado, R. F.; Lima, E. M. D.; Demir, S.; Dissemond, J.; Gunaydin, S. D.; Dorofeeva, I.; Ensina, L. F.; Ertas, R.; Ferrucci, S. M.; Figueras-Nart, I.; Fomina, D.; Franken, S. M.; Fukunaga, A.; Gimenez-Arnau, A. M.; Godse, K.; Goncalo, M.; Gotua, M.; Grattan, C.; Guillet, C.; Inomata, N.; Jakob, T.; Karakaya, G.; Kasperska-Zajac, A.; Katelaris, C. H.; Kosnik, M.; Krasowska, D.; Kulthanan, K.; Kumaran, M. S.; Lang, C.; Larco-Sousa, J. I.; Lazaridou, E.; Leslie, T. A.; Lippert, U.; Llosa, O. C.; Makris, M.; Marsland, A.; Medina, I. V.; Meshkova, R.; Palitot, E. B.; Parisi, C. A. S.; Pickert, J.; Ramon, G. D.; Rodriguez-Gonzalez, M.; Rosario, N.; Rudenko, M.; Rutkowski, K.; Sanchez, J.; Schliemann, S.; Sekerel, B. E.; Serpa, F. S.; Serra-Baldrich, E.; Song, Z. Q.; Soria, A.; Staevska, M.; Staubach, P.; Tagka, A.; Takahagi, S.; Thomsen, S. F.; Treudler, R.; Vadasz, Z.; Valle, S. O. R.; Van Doorn, M. B. A.; Vestergaard, C.; Wagner, N.; Wang, D. H.; Wang, L. C.; Wedi, B.; Xepapadaki, P.; Yücel, E.; Zalewska-Janowska, A.; Zhao, Z. T.; Zuberbier, T.; Maurer, M., School of Medicine, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Salman, A.; Cherrez-Ojeda, I.; Criado, P. R.; Peter, J.; Comert-Ozer, E.; Abuzakouk, M.; Agondi, R. C.; Al-Ahmad, M.; Altrichter, S.; Arnaout, R.; Arruda, L. K.; Asero, R.; Bauer, A.; Ben-Shoshan, M.; Bernstein, J. A.; Bizjak, M.; Boccon-Gibod, I.; Bonnekoh, H.; Bouillet, L.; Brzoza, Z.; Busse, P.; Campos, R. A.; Carne, E.; Conlon, N.; Criado, R. F.; Lima, E. M. D.; Demir, S.; Dissemond, J.; Gunaydin, S. D.; Dorofeeva, I.; Ensina, L. F.; Ertas, R.; Ferrucci, S. M.; Figueras-Nart, I.; Fomina, D.; Franken, S. M.; Fukunaga, A.; Gimenez-Arnau, A. M.; Godse, K.; Goncalo, M.; Gotua, M.; Grattan, C.; Guillet, C.; Inomata, N.; Jakob, T.; Karakaya, G.; Kasperska-Zajac, A.; Katelaris, C. H.; Kosnik, M.; Krasowska, D.; Kulthanan, K.; Kumaran, M. S.; Lang, C.; Larco-Sousa, J. I.; Lazaridou, E.; Leslie, T. A.; Lippert, U.; Llosa, O. C.; Makris, M.; Marsland, A.; Medina, I. V.; Meshkova, R.; Palitot, E. B.; Parisi, C. A. S.; Pickert, J.; Ramon, G. D.; Rodriguez-Gonzalez, M.; Rosario, N.; Rudenko, M.; Rutkowski, K.; Sanchez, J.; Schliemann, S.; Sekerel, B. E.; Serpa, F. S.; Serra-Baldrich, E.; Song, Z. Q.; Soria, A.; Staevska, M.; Staubach, P.; Tagka, A.; Takahagi, S.; Thomsen, S. F.; Treudler, R.; Vadasz, Z.; Valle, S. O. R.; Van Doorn, M. B. A.; Vestergaard, C.; Wagner, N.; Wang, D. H.; Wang, L. C.; Wedi, B.; Xepapadaki, P.; Yücel, E.; Zalewska-Janowska, A.; Zhao, Z. T.; Zuberbier, T.; Maurer, M., and School of Medicine

Abstract

Introduction: the COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: to understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and methods: our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results: the COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID-19. Conclusions: the COVID-19 pandemic brings major changes and challenges for CU patients and their physicians. The long-term consequences of these changes, especially the increased use of remote consultations, require careful evaluation., Novartis; Sanofi; Menarini Universidad Espiritu Santo; Takeda; Allakos; AstraZeneca; CSL Behring; Genentech; Pharming; GSK; Shire/Takada; BioCryst; ResTORbio; Pearl Therapeutics, CVS Health; Law offices of Levin; Riback; Adelman; Flangel; Vedder Price; Fresenius; Taiho; Kyowa Kirin; Tanabe; Korin; Uriach Pharma; Instituto Carlos III FEDER; Menarini; Amgen; Thermo Fisher; Avene; ALK‐Abello; Bencard/Allergy Therapeutics; Celgene; Allergopharma; Faes Farma; AbbVie; Janssen; Leo Pharma; Lilly; Roche; Genesis; Menlo Therapeutics; UCB; Pfizer; Almirall; Galderma; Allergika; Beiersdorf; Biocryst; Biogen Idec; BMS; Boehringer‐Ingelheim; Eli‐Lilly; Galderma; Hexal; Klosterfrau; LEO‐Pharma; LETI‐Pharma; L´Oreal; Medice; Octapharma; Pflüger; Pharming; Regeneron; Shire; ALK‐Abello; Fraunhofer‐IZI Leipzig; Hautnetz Leipzig/Westsachsen; MSD; HAL‐Allergy; Bencard; Nestle; Nutricia; Bayer Health Care; FAES; Henkel; Allakos; Argenx; Genentech Menarini; Moxie; Aralez; Celldex

Published
2020

37. The global burden of chronic urticaria for the patient and society*.

Author

Gonçalo, M., Gimenéz‐Arnau, A., Al‐Ahmad, M., Ben‐Shoshan, M., Bernstein, J.A., Ensina, L.F., Fomina, D., Galvàn, C.A., Godse, K., Grattan, C., Hide, M., Katelaris, C.H., Khoshkhui, M., Kocatürk, E., Kulthanan, K., Medina, I., Nasr, I., Peter, J., Staubach, P., and Wang, L.

Subjects
URTICARIA, PATIENTS' families, QUALITY of life, PURCHASING power parity, MIDDLE-aged women, CHRONICALLY ill
Abstract

Summary: Chronic urticaria (CU) affects about 1% of the world population of all ages, mostly young and middle‐aged women. It usually lasts for several years (> 1 year in 25–75% of patients) and often takes > 1 year before effective management is implemented. It presents as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) or both in the same person. More than 25% of cases are resistant to H1‐antihistamines, even at higher doses, and third‐ and fourth‐line therapies (omalizumab and ciclosporin) control the disease only in two‐thirds of H1‐antihistamine‐resistant patients. Here we review the impact of CU on different aspects of patients' quality of life and the burden of this chronic disease for the patient and society. CU may have a strong impact on health‐related quality of life (HRQoL), particularly when CSU is associated with angio‐oedema and/or CIndU (Dermatology Life Quality Index > 10 in 30% of patients). Comorbidities, such as anxiety and depression, which are present in more than 30% of patients with CSU, compound HRQoL impairment. Severe pruritus and the unpredictable occurrence of weals and angio‐oedema are responsible for sleep disorders; sexual dysfunction; limitations on daily life, work and sports activities; interfering with life within the family and in society; and patients' performance at school and work (6% absenteeism and 25% presenteeism). Apart from treatment costs, with annual values between 900 and 2400 purchasing power parity dollars (PPP$) in Europe and the USA, CU is associated with a high consumption of medical resources and other indirect costs, which may reach a total annual cost of PPP$ 15 550. Plain language summary available online [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

41. Magnetic Resonance Imaging on Sodium Nuclei: Potential Medical Applications of 23Na MRI.

Author

Sadykhov, E. G., Pirogov, Yu. A., Anisimov, N. V., Gulyaev, M. V., Pavlovskaya, G. E., Meersmann, T., Belyaev, V. N., and Fomina, D. V.

Abstract

Sodium is a key element in a living organism. The increase of its concentration is an indicator of many pathological conditions. 23Na magnetic resonance imaging (MRI) is a quantitative method that allows to determine the sodium content in tissues and organs in vivo. This method has not yet entered clinical practice widely, but it has already been used as a clinical research tool to investigate diseases such as brain tumors, breast cancer, stroke, multiple sclerosis, hypertension, diabetes, ischemic heart disease, osteoarthritis. The active development of the 23Na MRI is promoted by the growth of available magnetic fields, the expansion of hardware capabilities, and the development of pulse sequences with ultra-short echo time. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

42. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria

Author

Kocatürk, Emek, Salman, Andaç, Cherrez-Ojeda, Ivan, Criado, Paulo Ricardo, Peter, Jonny, Comert-Ozer, Elif, Abuzakouk, Mohamed, Câmara Agondi, Rosana, Al-Ahmad, Mona, Altrichter, Sabine, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Bauer, Andrea, Ben-Shoshan, Moshe, Bernstein, Jonathan, Bizjak, Mojca, Boccon-Gibod, Isabelle, Bonnekoh, Hanna, Bouillet, Laurence, Brzoza, Zenon, Busse, Paula, Campos, Regis A., Carne, Emily, Conlon, Niall, Criado, Roberta Fachini Jardim, De Souza Lima, Eduardo Magalhães, Demir, Semra, Dissemond, Joachim, Doğan Günaydın, Sibel, Dorofeeva, Irina, Ensina, Luis Felipe, Ertaş, Ragip, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fomina, Daria, Franken, Sylvie M., Fukunaga, Atsushi, Giménez Arnau, Ana M, Godse, Kiran, Gonçalo, Margarida, Gotua, Maia, Grattan, Clive, Guillet, Carole, Inomata, Naoko, Jakob, Thilo, Karakaya, Gul, Kasperska-Zając, Alicja, Katelaris, Constance H., Košnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M.Sendhil, Lang, Claudia, Larco-Sousa, José Ignacio, Lazaridou, Elisavet, Leslie, Tabi Anika, Lippert, Undine, Calderón llosa, Oscar, Makris, Michael, Marsland, Alexander, Medina, Iris V., Meshkova, Raisa, Bastos Palitot, Esther, Parisi, Claudio A.S., Pickert, Julia, Ramon, Germán D., Rodríguez-Gonzalez, Mónica, Rosario, Nelson, Rudenko, Michael, Rutkowski, Krzysztof, Sánchez Caraballo, Jorge Mario, Schliemann, Sibylle, Sekerel, Bulent Enis, Serpa, Faradiba S., Serra-Baldrich, E, Song, Zhiqiang, Soria, Angèle, Staevska, Maria, Staubach, Petra, Tagka, Anna, Takahagi, Shunsuke, Thomsen, Simon Francis, Treudler, Regina, Vadasz, Zahava, Rodrigues Valle, Solange Oliveira, Van Doorn, Martijn B.A., Vestergaard, Christian, Wagner, Nicola, Wang, Dahu, Wang, Liangchun, Wedi, Bettina, Xepapadaki, Paraskevi, Yücel, Esra, Zalewska-Janowska, Anna, Zhao, Zuotao, Zuberbier, Torsten, Maurer, Marcus, Universitat Autònoma de Barcelona, Dermatology, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Salman, A., Cherrez-Ojeda, I., Criado, P. R., Peter, J., Comert-Ozer, E., Abuzakouk, M., Agondi, R. C., Al-Ahmad, M., Altrichter, S., Arnaout, R., Arruda, L. K., Asero, R., Bauer, A., Ben-Shoshan, M., Bernstein, J. A., Bizjak, M., Boccon-Gibod, I., Bonnekoh, H., Bouillet, L., Brzoza, Z., Busse, P., Campos, R. A., Carne, E., Conlon, N., Criado, R. F., Lima, E. M. D., Demir, S., Dissemond, J., Gunaydin, S. D., Dorofeeva, I., Ensina, L. F., Ertas, R., Ferrucci, S. M., Figueras-Nart, I., Fomina, D., Franken, S. M., Fukunaga, A., Gimenez-Arnau, A. M., Godse, K., Goncalo, M., Gotua, M., Grattan, C., Guillet, C., Inomata, N., Jakob, T., Karakaya, G., Kasperska-Zajac, A., Katelaris, C. H., Kosnik, M., Krasowska, D., Kulthanan, K., Kumaran, M. S., Lang, C., Larco-Sousa, J. I., Lazaridou, E., Leslie, T. A., Lippert, U., Llosa, O. C., Makris, M., Marsland, A., Medina, I. V., Meshkova, R., Palitot, E. B., Parisi, C. A. S., Pickert, J., Ramon, G. D., Rodriguez-Gonzalez, M., Rosario, N., Rudenko, M., Rutkowski, K., Sanchez, J., Schliemann, S., Sekerel, B. E., Serpa, F. S., Serra-Baldrich, E., Song, Z. Q., Soria, A., Staevska, M., Staubach, P., Tagka, A., Takahagi, S., Thomsen, S. F., Treudler, R., Vadasz, Z., Valle, S. O. R., Van Doorn, M. B. A., Vestergaard, C., Wagner, N., Wang, D. H., Wang, L. C., Wedi, B., Xepapadaki, P., Yücel, E., Zalewska-Janowska, A., Zhao, Z. T., Zuberbier, T., Maurer, M., School of Medicine, AII - Infectious diseases, Kocaturk, Emek, Salman, Andac, Cherrez-Ojeda, Ivan, Criado, Paulo Ricardo, Peter, Jonny, Comert-Ozer, Elif, Abuzakouk, Mohamed, Agondi, Rosana Camara, Al-Ahmad, Mona, Altrichter, Sabine, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Bauer, Andrea, Ben-Shoshan, Moshe, Bernstein, Jonathan A., Bizjak, Mojca, Boccon-Gibod, Isabelle, Bonnekoh, Hanna, Bouillet, Laurence, Brzoza, Zenon, Busse, Paula, Campos, Regis A., Carne, Emily, Conlon, Niall, Criado, Roberta F., de Souza Lima, Eduardo M., Demir, Semra, Dissemond, Joachim, Gunaydin, Sibel Dogan, Dorofeeva, Irina, Ensina, Luis Felipe, Ertas, Ragip, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fomina, Daria, Franken, Sylvie M., Fukunaga, Atsushi, Gimenez-Arnau, Ana M., Godse, Kiran, Goncalo, Margarida, Gotua, Maia, Grattan, Clive, Guillet, Carole, Inomata, Naoko, Jakob, Thilo, Karakaya, Gul, Kasperska-Zajac, Alicja, Katelaris, Constance H., Kosnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M. Sendhil, Lang, Claudia, Ignacio Larco-Sousa, Jose, Lazaridou, Elisavet, Leslie, Tabi Anika, Lippert, Undine, Llosa, Oscar Calderon, Makris, Michael, Marsland, Alexander, Medina, Iris, V, Meshkova, Raisa, Palitot, Esther Bastos, Parisi, Claudio A. S., Pickert, Julia, Ramon, German D., Rodriguez-Gonzalez, Monica, Rosario, Nelson, Rudenko, Michael, Rutkowski, Krzysztof, Sanchez, Jorge, Schliemann, Sibylle, Sekerel, Bulent Enis, Serpa, Faradiba S., Serra-Baldrich, Esther, Song, Zhiqiang, Soria, Angele, Staevska, Maria, Staubach, Petra, Tagka, Anna, Takahagi, Shunsuke, Thomsen, Simon Francis, Treudler, Regina, Vadasz, Zahava, Rodrigues Valle, Solange Oliveira, Van Doorn, Martijn B. A., Vestergaard, Christian, Wagner, Nicola, Wang, Dahu, Wang, Liangchun, Wedi, Bettina, Xepapadaki, Paraskevi, Yucel, Esra, Zalewska-Janowska, Anna, Zhao, Zuotao, Zuberbier, Torsten, and Maurer, Marcus

Subjects
Male, 0301 basic medicine, STRESS, Exacerbation, UCARE, pandemije, Medizin, Omalizumab, SERUM, chronic urticaria, 0302 clinical medicine, Pandemic, Health care, Immunology and Allergy, Chronic Urticaria, treatment, Chronic urticaria, COVID-19, Cyclosporine, SARS-CoV-2, Treatment, zdravljenje, ASSOCIATION, Middle Aged, cyclosporine, omalizumab, pandemic, kronična urtikarija, INFECTIONS, GA(2)LEN, Female, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Coronavirus disease 2019 (COVID-19), Immunology, udc:616-097, pandemics, ciklosporin, Young Adult, 03 medical and health sciences, Patient referral, medicine, Humans, In patient, Patient Reported Outcome Measures, Aged, Internet, business.industry, DEFINITION, Medicine, Allergy, Cross-Sectional Studies, 030104 developmental biology, 030228 respiratory system, Emergency medicine, business
Abstract

Introduction: the COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: to understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and methods: our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results: the COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID-19. Conclusions: the COVID-19 pandemic brings major changes and challenges for CU patients and their physicians. The long-term consequences of these changes, especially the increased use of remote consultations, require careful evaluation., Novartis; Sanofi; Menarini Universidad Espiritu Santo; Takeda; Allakos; AstraZeneca; CSL Behring; Genentech; Pharming; GSK; Shire/Takada; BioCryst; ResTORbio; Pearl Therapeutics, CVS Health; Law offices of Levin; Riback; Adelman; Flangel; Vedder Price; Fresenius; Taiho; Kyowa Kirin; Tanabe; Korin; Uriach Pharma; Instituto Carlos III FEDER; Menarini; Amgen; Thermo Fisher; Avene; ALK‐Abello; Bencard/Allergy Therapeutics; Celgene; Allergopharma; Faes Farma; AbbVie; Janssen; Leo Pharma; Lilly; Roche; Genesis; Menlo Therapeutics; UCB; Pfizer; Almirall; Galderma; Allergika; Beiersdorf; Biocryst; Biogen Idec; BMS; Boehringer‐Ingelheim; Eli‐Lilly; Galderma; Hexal; Klosterfrau; LEO‐Pharma; LETI‐Pharma; L´Oreal; Medice; Octapharma; Pflüger; Pharming; Regeneron; Shire; ALK‐Abello; Fraunhofer‐IZI Leipzig; Hautnetz Leipzig/Westsachsen; MSD; HAL‐Allergy; Bencard; Nestle; Nutricia; Bayer Health Care; FAES; Henkel; Allakos; Argenx; Genentech Menarini; Moxie; Aralez; Celldex

Published
2021
Full Text
View/download PDF

43. How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study

Author

Emek Kocatürk, Roberta F. Criado, Carla Ritchie, Mohamed Abuzakouk, Simon Francis Thomsen, Annia Cherrez, Jose Ignacio Larco, Carole Guillet, Agnieszka Sikora, Zuotao Zhao, Deepa Grandon, Marcus Maurer, Elena Kovalkova, Miguel Felix, Ana Giménez-Arnau, Ivan Cherrez-Ojeda, Daria Fomina, Karsten Weller, Alicja Kasperska-Zajac, Eduardo Magalhães de Souza Lima, Emanuel Vanegas, Sofia Cherrez, Paraskevi Xepapadaki, Michael Makris, Edgar Emilio Matos Benavides, Kiran Godse, Sahar Rastgoo, Rasmus Robin Maurer, Martijn B. A. van Doorn, Luis Felipe Ensina, Valeria L. Mata, Maryam Khoshkhui, Andrea Bauer, Solange Oliveira Rodrigues Valle, Nimmagadda Dheeraj Rao, German D. Ramon, Markus Magerl, Dermatology, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Cherrez-Ojeda, I., Vanegas, E., Cherrez, A., Felix, M., Weller, K., Magerl, M., Maurer, R. R., Mata, V. L., Kasperska-Zajac, A., Sikora, A., Fomina, D., Kovalkova, E., Godse, K., Rao, N. D., Khoshkhui, M., Rastgoo, S., Criado, R. F., Abuzakouk, M., Grandon, D., Van Doorn, M. B. A., Oliveira Rodrigues Valle, S., De Souza Lima, E. M., Thomsen, S. F., Ramón, G. D., Matos Benavides, E. E., Bauer, A., Giménez-Arnau, A. M., Guillet, C., Larco, J. I., Zhao, Z.- T., Makris, M., Ritchie, C., Xepapadaki, P., Ensina, L. F., Cherrez, S., Maurer, M., Koç University Hospital, and School of Medicine

Subjects
Pulmonary and Respiratory Medicine, Higher education, media_common.quotation_subject, Immunology, WhatsApp, Information and communication technologies, NEEDS, Article, 03 medical and health sciences, 0302 clinical medicine, PHYSICIANS, Excellence, ComputerApplications_MISCELLANEOUS, Health care, parasitic diseases, Immunology and Allergy, Medicine, 030223 otorhinolaryngology, Chronic urticaria, media_common, Medical education, Internet, Allergy, E-mail, business.industry, RC581-607, 030228 respiratory system, Information and Communications Technology, e-mail, The Internet, ICTS, Rural area, Immunologic diseases. Allergy, business, BURDEN
Abstract

Background: patients with chronic urticaria (CU) are increasingly using information and communication technologies (ICTs) to manage their health. What CU patients expect from ICTs and which ICTs they prefer remains unknown. We assessed why CU patients use ICTs, which ones they prefer, and what drives their expectations and choices. Methods: in this cross-sectional study, 1841 patients across 17 countries were recruited at UCAREs (Urticaria Centers of Reference and Excellence). Patients with CU who were >12 years old completed a 23-item questionnaire. Results: most patients were interested in receiving disease information (87.3%), asking physicians about CU (84.1%), and communicating with other patients through ICTs (65.6%). For receiving disease information, patients preferred one-to-one and one-to-many ICTs, especially web browsers. One-to-one ICTs were also the ICTs of choice for asking physicians about urticaria and for communicating with other patients, and e-mail and WhatsApp were the preferred ICTs, respectively. Many-to-many ICTs such as Facebook, Instagram, LinkedIn, and Twitter were least preferred for all 3 purposes. Living in rural areas and higher education were linked to higher odds of being interested in receiving disease information, asking physicians, and communicating with patients through ICTs. Conclusions: most patients and especially patients with higher education who live in rural areas are interested in using ICTs for their healthcare, but prefer different ICTs for different purposes, ie, web browsers for obtaining information, e-mail for asking physicians, and WhatsApp for communicating with other patients. Our findings may help to improve ICTs for CU., GA2LEN Network of Urticaria Centers of Reference and Excellence (UCARE); World Allergy Organization (WAO)

Published
2021
Full Text
View/download PDF

44. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

Author

François-Xavier Lescure, Hitoshi Honda, Robert A Fowler, Jennifer Sloane Lazar, Genming Shi, Peter Wung, Naimish Patel, Owen Hagino, Ignacio J. Bazzalo, Marcelo M. Casas, Sebastián A. Nuñez, Yael Pere, Carlos M. Ibarrola, Marco A. Solis Aramayo, Maria C. Cuesta, Andrea E. Duarte, Pablo M. Gutierrez Fernandez, Maria A. Iannantuono, Erica A. Miyazaki, Javier P. Silvio, Dario G. Scublinsky, Alessandra Bales, Daniela Catarino, Elie Fiss, Sara Mohrbacher, Victor Sato, Antonio Baylao, Adilson Cavalcante, Francini Correa, Celso A. de Andrade, Juvencio Furtado, Nelson Ribeiro Filho, Valéria Telles, Leopoldo T. Trevelin, Ricardo Vipich, Rodrigo Boldo, Paula Borges, Suzana Lobo, Graziela Luckemeyer, Luana Machado, Maysa B. Alves, Ana C. Iglessias, Marianna M. Lago, Daniel W. Santos, Hugo Chapdelaine, Emilia L. Falcone, Rahima Jamal, Me-Linh Luong, Madeleine Durand, Stephane Doucet, François-Martin Carrier, Bryan A. Coburn, Lorenzo Del Sorbo, Sharon L. Walmsley, Sara Belga, Luke Y. Chen, Allison D. Mah, Theodore Steiner, Alissa J. Wright, J. Hajek, Neill Adhikari, Robert A. Fowler, Nick Daneman, Kosar A. Khwaja, Jason Shahin, Carolina Gonzalez, Rafael Silva, Marcelo Lindh, Gabriel Maluenda, Patricia Fernandez, Maite Oyonarte, Martin Lasso, Alexandre Boyer, Didier Bronnimann, Hoang-Nam Bui, Charles Cazanave, Helene Chaussade, Arnaud Desclaux, Mailys Ducours, Alexandre Duvignaud, Denis Malvy, Lisa Martin, Didier Neau, Duc Nguyen, Thierry Pistone, Gaetane Soubrane-Wirth, Julie Leitao, Clotilde Allavena, Charlotte Biron, Sabelline Bouchez, Benjamin Gaborit, Antoine Gregoire, Paul Le Turnier, Anne-Sophie Lecompte, Raphael Lecomte, Maeva Lefebvre, Francois Raffi, David Boutoille, Pascale H. Morineau, Romain Guéry, Emmanuel Chatelus, Nathalie Dumoussaud, Renaud Felten, Florina Luca, Bernard Goichot, Francis Schneider, Marie-Caroline Taquet, Matthieu Groh, Mathilde Roumier, Mathilde Neuville, Antoine Bachelard, Valentina Isernia, F-Xavier Lescure, Bao-Chau Phung, Anne Rachline, Aurelie Sautereau, Dorothee Vallois, Yves Bleher, Delphine Boucher, Clémentine Coudon, Jean Esnault, Thomas Guimard, Sophie Leautez-Nainville, Dominique Merrien, Marine Morrier, Pauline Motte-Vincent, Romain Gabeff, Hélène Leclerc, Céline Cozic, Romain Decours, Ronan Février, Gwenhael Colin, Sophie Abgrall, Dorothee Vignes, Raluca Sterpu, Mira Kuellmar, Melanie Meersch-Dini, Raphael Weiss, Alexander Zarbock, Christiane Antony, Marc Berger, Thorsten Brenner, Christian Taube, Frank Herbstreit, Sebastian Dolff, Margarethe Konik, Karsten Schmidt, Markus Zettler, Oliver Witzke, Boris Boell, Jorge Garcia Borrega, Philipp Koehler, Thomas Zander, Fabian Dusse, Othman Al-Sawaf, Philipp Köhler, Dennis Eichenauer, Matthias Kochanek, Alexander Shimabukuro-Vornhagen, Sibylle Mellinghoff, Annika Claßen, Jan-Michel Heger, Charlotte Meyer-Schwickerath, Paul Liedgens, Katrin Heindel, Ana Belkin, Asaf Biber, Mayan Gilboa, Itzchak Levy, Vladislav Litachevsky, Galia Rahav, Anat Finesod Wiedner, Tal Zilberman-Daniels, Yonatan Oster, Jacob Strahilevitz, Sigal Sviri, Elena M. Baldissera, Corrado Campochiaro, Giulio Cavalli, Lorenzo Dagna, Giacomo De Luca, Emanuel Della Torre, Alessandro Tomelleri, Davide Bernasconi De Luca, Amedeo F. Capetti, Massimo Coen, Maria V. Cossu, Massimo Galli, Andrea Giacomelli, Guido A. Gubertini, Stefano Rusconi, Giulia J. Burastero, Margherita Digaetano, Giovanni Guaraldi, Marianna Meschiari, Cristina Mussini, Cinzia Puzzolante, Sara Volpi, Marina Aiello, Alarico Ariani, Alfredo A. Chetta, Annalisa Frizzelli, Andrea Ticinesi, Domenico Tuttolomondo, Stefano Aliberti, Francesco B. Blasi, Marta F. Di Pasquale, Sofia Misuraca, Tommaso Pilocane, Edoardo Simonetta, Alessio M. Aghelmo, Claudio Angelini, Enrico Brunetta, Giorgio W. Canonica, Michele Ciccarelli, Sara Dal Farra, Maria De Santis, Sebastian Ferri, Marco Folci, Giacomo M. Guidelli, Enrico M. Heffler, Ferdinando Loiacono, Giacomo Malipiero, Giovanni Paoletti, Rosa Pedale, Francesca A. Puggioni, Francesca Racca, Aurora Zumbo, Morihiko Satou, Tatyana Lisun, Denis Protsenko, Nikolay Rubtsov, Irina Beloglazova, Daria Fomina, Mariana Lysenko, Sofia Serdotetskova, Vitali Firstov, Ivan Gordeev, Ilia Kokorin, Ksenia Komissarova, Nina Lapochkina, Elena Luchinkina, Valentin Malimon, Sevinch Mamedguseyinova, Ksenia Polubatonova, Natalia Suvorova, Jose Arribas, Alberto M. Borobia Perez, Fernando de la Calle Prieto, Juan Carlos Figueira, Rocio Motejano Sanchez, Marta Mora-Rillo, Concepcion Prados Sanchez, Javier Queiruga Parada, Francisco Fernandez Arnalich, Maria Guerro Barrientos, Alejandro Bendala Estrada, Aranzazu Caballero Marcos, Maria E. Garcia Leoni, Rita García-Martínez, Ana María Collado, Patricia Munoz Garcia, Ana Torres do Rego, María V. Villalba García, Almudena Burrillo, Maricela Valerio Minero, Paloma Gijon Vidaurreta, Sonsoles Infante Herrero, Elena Velilla, Marina Machado, Maria Olmedo, Blanca Pinilla, Benito Almirante Gragera, Maria de la Esperanza Cañas Ruano, Sofia Contreras Medina, Alejandro Cortés Herrera, Vicenç Falcó Ferrer, Ricard Ferrer Roca, Xavier Nuvials Casals, Esteve Ribera Pascuet, Paula Suanzes Diez, Pedro Rebollo Castro, Felipe Garcia Alcaide, Alejandro Soriano, Aina Oliver Caldes, Ana González Cordón, Celia Cardozo, Lorena De la Mora Cañizo, Romina Pena López, Sandra Chamorro, Clara Crespillo-Andujar, Rosa Escudero Sanchez, Jesús Fortún-Abete, Begoña Monge-Maillo, Ana Moreno Zamora, Francesca Norman, Matilde Sanchez Conde, Sergio Serrano Villar, Pilar Vizcarra, Lescure, F. -X., Honda, H., Fowler, R. A., Lazar, J. S., Shi, G., Wung, P., Patel, N., Hagino, O., Bazzalo, I. J., Casas, M. M., Nunez, S. A., Pere, Y., Ibarrola, C. M., Solis Aramayo, M. A., Cuesta, M. C., Duarte, A. E., Gutierrez Fernandez, P. M., Iannantuono, M. A., Miyazaki, E. A., Silvio, J. P., Scublinsky, D. G., Bales, A., Catarino, D., Fiss, E., Mohrbacher, S., Sato, V., Baylao, A., Cavalcante, A., Correa, F., de Andrade, C. A., Furtado, J., Ribeiro Filho, N., Telles, V., Trevelin, L. T., Vipich, R., Boldo, R., Borges, P., Lobo, S., Luckemeyer, G., Machado, L., Alves, M. B., Iglessias, A. C., Lago, M. M., Santos, D. W., Chapdelaine, H., Falcone, E. L., Jamal, R., Luong, M. -L., Durand, M., Doucet, S., Carrier, F. -M., Coburn, B. A., Del Sorbo, L., Walmsley, S. L., Belga, S., Chen, L. Y., Mah, A. D., Steiner, T., Wright, A. J., Hajek, J., Adhikari, N., Daneman, N., Khwaja, K. A., Shahin, J., Gonzalez, C., Silva, R., Lindh, M., Maluenda, G., Fernandez, P., Oyonarte, M., Lasso, M., Boyer, A., Bronnimann, D., Bui, H. -N., Cazanave, C., Chaussade, H., Desclaux, A., Ducours, M., Duvignaud, A., Malvy, D., Martin, L., Neau, D., Nguyen, D., Pistone, T., Soubrane-Wirth, G., Leitao, J., Allavena, C., Biron, C., Bouchez, S., Gaborit, B., Gregoire, A., Le Turnier, P., Lecompte, A. -S., Lecomte, R., Lefebvre, M., Raffi, F., Boutoille, D., Morineau, P. H., Guery, R., Chatelus, E., Dumoussaud, N., Felten, R., Luca, F., Goichot, B., Schneider, F., Taquet, M. -C., Groh, M., Roumier, M., Neuville, M., Bachelard, A., Isernia, V., Phung, B. -C., Rachline, A., Sautereau, A., Vallois, D., Bleher, Y., Boucher, D., Coudon, C., Esnault, J., Guimard, T., Leautez-Nainville, S., Merrien, D., Morrier, M., Motte-Vincent, P., Gabeff, R., Leclerc, H., Cozic, C., Decours, R., Fevrier, R., Colin, G., Abgrall, S., Vignes, D., Sterpu, R., Kuellmar, M., Meersch-Dini, M., Weiss, R., Zarbock, A., Antony, C., Berger, M., Brenner, T., Taube, C., Herbstreit, F., Dolff, S., Konik, M., Schmidt, K., Zettler, M., Witzke, O., Boell, B., Garcia Borrega, J., Koehler, P., Zander, T., Dusse, F., Al-Sawaf, O., Kohler, P., Eichenauer, D., Kochanek, M., Shimabukuro-Vornhagen, A., Mellinghoff, S., Classen, A., Heger, J. -M., Meyer-Schwickerath, C., Liedgens, P., Heindel, K., Belkin, A., Biber, A., Gilboa, M., Levy, I., Litachevsky, V., Rahav, G., Finesod Wiedner, A., Zilberman-Daniels, T., Oster, Y., Strahilevitz, J., Sviri, S., Baldissera, E. M., Campochiaro, C., Cavalli, G., Dagna, L., De Luca, Giacomo., Della Torre, E., Tomelleri, A., Bernasconi De Luca, D., Capetti, A. F., Coen, M., Cossu, M. V., Galli, M., Giacomelli, A., Gubertini, G. A., Rusconi, S., Burastero, G. J., Digaetano, M., Guaraldi, G., Meschiari, M., Mussini, C., Puzzolante, C., Volpi, S., Aiello, M., Ariani, A., Chetta, A. A., Frizzelli, A., Ticinesi, A., Tuttolomondo, D., Aliberti, S., Blasi, F. B., Di Pasquale, M. F., Misuraca, S., Pilocane, T., Simonetta, E., Aghelmo, A. M., Angelini, C., Brunetta, E., Canonica, G. W., Ciccarelli, M., Dal Farra, S., De Santis, M., Ferri, S., Folci, M., Guidelli, G. M., Heffler, E. M., Loiacono, F., Malipiero, G., Paoletti, G., Pedale, R., Puggioni, F. A., Racca, F., Zumbo, A., Satou, M., Lisun, T., Protsenko, D., Rubtsov, N., Beloglazova, I., Fomina, D., Lysenko, M., Serdotetskova, S., Firstov, V., Gordeev, I., Kokorin, I., Komissarova, K., Lapochkina, N., Luchinkina, E., Malimon, V., Mamedguseyinova, S., Polubatonova, K., Suvorova, N., Arribas, J., Borobia Perez, A. M., de la Calle Prieto, F., Figueira, J. C., Motejano Sanchez, R., Mora-Rillo, M., Prados Sanchez, C., Queiruga Parada, J., Fernandez Arnalich, F., Guerro Barrientos, M., Bendala Estrada, A., Caballero Marcos, A., Garcia Leoni, M. E., Garcia-Martinez, R., Collado, A. M., Munoz Garcia, P., Torres do Rego, A., Villalba Garcia, M. V., Burrillo, A., Valerio Minero, M., Gijon Vidaurreta, P., Infante Herrero, S., Velilla, E., Machado, M., Olmedo, M., Pinilla, B., Almirante Gragera, B., Canas Ruano, M. D. L. E., Contreras Medina, S., Cortes Herrera, A., Falco Ferrer, V., Ferrer Roca, R., Nuvials Casals, X., Ribera Pascuet, E., Suanzes Diez, P., Rebollo Castro, P., Garcia Alcaide, F., Soriano, A., Oliver Caldes, A., Gonzalez Cordon, A., Cardozo, C., De la Mora Canizo, L., Pena Lopez, R., Chamorro, S., Crespillo-Andujar, C., Escudero Sanchez, R., Fortun-Abete, J., Monge-Maillo, B., Moreno Zamora, A., Norman, F., Sanchez Conde, M., Serrano Villar, S., and Vizcarra, P.

Subjects
Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Critical Care, International Cooperation, Population, Antibodies, Monoclonal, Humanized, Placebo, Severity of Illness Index, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Intensive care, Severity of illness, medicine, Clinical endpoint, Humans, Immunologic Factors, 030212 general & internal medicine, Mortality, education, Respiratory Distress Syndrome, education.field_of_study, Dose-Response Relationship, Drug, SARS-CoV-2, business.industry, Hazard ratio, COVID-19, Articles, Middle Aged, Receptors, Interleukin-6, Sarilumab, Treatment Outcome, 030228 respiratory system, Female, Drug Monitoring, Cytokine Release Syndrome, business
Abstract

Summary Background Elevated proinflammatory cytokines are associated with greater COVID-19 severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19. Methods We did a 60-day, randomised, double-blind, placebo-controlled, multinational phase 3 trial at 45 hospitals in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain. We included adults (≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection and pneumonia, who required oxygen supplementation or intensive care. Patients were randomly assigned (2:2:1 with permuted blocks of five) to receive intravenous sarilumab 400 mg, sarilumab 200 mg, or placebo. Patients, care providers, outcome assessors, and investigators remained masked to assigned intervention throughout the course of the study. The primary endpoint was time to clinical improvement of two or more points (seven point scale ranging from 1 [death] to 7 [discharged from hospital]) in the modified intention-to-treat population. The key secondary endpoint was proportion of patients alive at day 29. Safety outcomes included adverse events and laboratory assessments. This study is registered with ClinicalTrials.gov, NCT04327388; EudraCT, 2020-001162-12; and WHO, U1111-1249-6021. Findings Between March 28 and July 3, 2020, of 431 patients who were screened, 420 patients were randomly assigned and 416 received placebo (n=84 [20%]), sarilumab 200 mg (n=159 [38%]), or sarilumab 400 mg (n=173 [42%]). At day 29, no significant differences were seen in median time to an improvement of two or more points between placebo (12·0 days [95% CI 9·0 to 15·0]) and sarilumab 200 mg (10·0 days [9·0 to 12·0]; hazard ratio [HR] 1·03 [95% CI 0·75 to 1·40]; log-rank p=0·96) or sarilumab 400 mg (10·0 days [9·0 to 13·0]; HR 1·14 [95% CI 0·84 to 1·54]; log-rank p=0·34), or in proportions of patients alive (77 [92%] of 84 patients in the placebo group; 143 [90%] of 159 patients in the sarilumab 200 mg group; difference −1·7 [−9·3 to 5·8]; p=0·63 vs placebo; and 159 [92%] of 173 patients in the sarilumab 400 mg group; difference 0·2 [−6·9 to 7·4]; p=0·85 vs placebo). At day 29, there were numerical, non-significant survival differences between sarilumab 400 mg (88%) and placebo (79%; difference +8·9% [95% CI −7·7 to 25·5]; p=0·25) for patients who had critical disease. No unexpected safety signals were seen. The rates of treatment-emergent adverse events were 65% (55 of 84) in the placebo group, 65% (103 of 159) in the sarilumab 200 mg group, and 70% (121 of 173) in the sarilumab 400 mg group, and of those leading to death 11% (nine of 84) were in the placebo group, 11% (17 of 159) were in the sarilumab 200 mg group, and 10% (18 of 173) were in the sarilumab 400 mg group. Interpretation This trial did not show efficacy of sarilumab in patients admitted to hospital with COVID-19 and receiving supplemental oxygen. Adequately powered trials of targeted immunomodulatory therapies assessing survival as a primary endpoint are suggested in patients with critical COVID-19. Funding Sanofi and Regeneron Pharmaceuticals.

Published
2021

45. Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis.

Author

Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, Rademaker M, Fomina D, Gutermuth J, Ahn J, Valenzuela F, Ameen M, Steinhoff M, Kirchhof MG, Lio P, and Wollenberg A

Subjects
Humans, Dermatitis, Atopic drug therapy, Dermatitis, Atopic therapy, Decision Making, Shared, Severity of Illness Index, Consensus
Abstract

Background: Current treat-to-target recommendations for atopic dermatitis (AD) may not include high enough treatment targets and do not fully consider patient needs., Objective: To develop recommendations for optimized AD management, including disease severity assessments, treatment goals and targets, and guidance for treatment escalation/modification., Methods: An international group of expert dermatologists drafted a series of recommendations for AD management using insights from a global patient study and 87 expert dermatologists from 44 countries. Experts voted on recommendations using a modified eDelphi voting process., Results: The Aiming High in Eczema/Atopic Dermatitis (AHEAD) recommendations establish a novel approach to AD management, incorporating shared decision-making and a concept for minimal disease activity (MDA). Consensus (≥70% agreement) was reached for all recommendations in 1 round of voting; strong consensus (≥90% agreement) was reached for 30/34 recommendations. In the AHEAD approach, patients select their most troublesome AD feature(s); the clinician chooses a corresponding patient-reported severity measure and objective severity measure. Treatment targets are chosen from a list of 'moderate' and 'optimal' targets, with achievement of 'optimal' targets defined as MDA., Conclusions: Patient and expert insights led to the development of AHEAD recommendations, which establish a novel approach to AD management. Patients were not involved in the eDelphi voting process used to generate consensus on each recommendation. However, patient perspectives were captured in a global, qualitative patient research study that was considered by the experts in their initial drafting of the recommendations., (© 2024 The Author(s). Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.)

Published
2024
Full Text
View/download PDF

46. Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring: A CRUSE® mobile health study.

Author

Sousa-Pinto B, Ramanauskaite A, Neisinger S, Witte-Händel E, Gimenez-Arnau AM, Guillet C, Parisi CAS, Katelaris CH, Fomina D, Larenas-Linnemann D, García E, Kocatürk E, Siebenhaar F, Lima H, Kaidashev I, Nasr I, Canales IO, Ojeda IC, Hébert J, Bousquet J, Bernstein JA, Peter J, Sanchez J, Sousa JIL, Kulthanan K, Weller K, Godse K, Rutkowski K, Lapina L, Bouillet L, Han LL, Ensina LF, Gonçalo M, Magerl M, van Doorn M, Metz M, Khoshkhui M, Hide M, Türk M, Kurjāne N, Conlon N, Salameh P, Kolkhir P, Asero R, Stepanenko R, Altrichter S, Gil-Mata S, Thomsen SF, Zuberbier T, Tsaryk V, Ye YM, Brzoza Z, Zhao Z, and Maurer M

Abstract

Background: CRUSE® is an app that allows patients with chronic spontaneous urticaria (CSU) to monitor their daily disease activity through the use of visual analogue scales (VASs). We aimed to determine the concurrent validity, reliability, responsiveness and minimal important difference (MID) of CRUSE® VASs., Methods: We evaluated the properties of three daily VASs: VAS for how much patients were affected by their CSU ('VAS urticaria'), VAS for the impact of urticaria on work/school productivity ('VAS productivity') and the VAS of EQ-5D. Concurrent validity was assessed by measuring the association between each VAS and the Urticaria Activity Score (UAS). Intra-rater reliability was determined based on the data of users providing multiple daily questionnaires within the same day. Test-retest reliability and responsiveness (ability to change), respectively, were tested in clinically stable and clinically unstable users. MIDs were determined using distribution-based methods., Results: We included 5938 patients (67,380 days). Concurrent validity was high, with VAS urticaria being more strongly associated with the UAS score than the remaining VASs. Intra-rater reliability was also high, with intraclass correlation coefficients (ICC) being above 0.950 for all VASs. Moderate-high test-retest reliability and responsiveness were observed, with reliability ICC being highest for VAS EQ-5D and responsiveness being highest for VAS urticaria. The MID for VAS urticaria was 17 (out of 100) units, compared to 15 units for VAS productivity and 11 units for VAS EQ-5D., Conclusion: Daily VASs for CSU available in the CRUSE® app display high concurrent validity and intra-rater reliability and moderate-high test-retest reliability and responsiveness., (© 2024 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

47. The Chronic Angioedema Registry (CARE): Rationale, Methods and Implementation.

Author

Buttgereit T, Aulenbacher F, Gutsche A, Kolkhir P, Weller K, Vera Ayala C, Magerl M, Farkas H, Grumach AS, Aygören-Pürsün E, Bara N, Ben-Shoshan M, Bernstein J, Betschel S, Bouillet L, Caballero T, Cancian M, Castaldo AJ, Cimbollek S, Cohn DM, Craig T, Fomina D, Gelincik A, Grivcheva-Panovska V, Jindal A, Katelaris C, Kessel A, Kinaciyan T, Longhurst HJ, Martinez-Saguer I, Riedl M, Schöffl C, Staubach P, Zanichelli A, Zhi Y, Balle Boysen H, Fok JS, Li PH, Hakl R, Hide M, Peter J, and Maurer M

Subjects
Humans, Chronic Disease, Female, Male, Registries, Angioedema epidemiology, Angioedema diagnosis
Published
2024
Full Text
View/download PDF

48. Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus.

Author

Reshef A, Buttgereit T, Betschel SD, Caballero T, Farkas H, Grumach AS, Hide M, Jindal AK, Longhurst H, Peter J, Riedl MA, Zhi Y, Aberer W, Abuzakouk M, Al Farsi T, Al Sukaiti N, Al-Ahmad M, Altrichter S, Aygören-Pürsün E, Baeza ML, Bara NA, Bauer A, Bernstein JA, Boccon-Gibod I, Bonnekoh H, Bouillet L, Brzoza Z, Bygum A, Calderon O, de Albuquerque Campos R, Campos Romero FH, Cancian M, Chong-Neto HJ, Christoff G, Cimbollek S, Cohn DM, Craig T, Danilycheva I, Darlenski R, Du-Thanh A, Ensina LF, Fomina D, Fonacier L, Fukunaga A, Gelincik A, Giavina-Bianchi P, Godse K, Gompels M, Goncalo M, Gotua M, Guidos-Fogelbach G, Guilarte M, Kasperska-Zajac A, Katelaris CH, Kinaciyan T, Kolkhir P, Kulthanan K, Kurowski M, Latysheva E, Lauerma A, Launay D, Lleonart R, Lumry W, Malbran A, Ali RM, Nasr I, Nieto-Martinez S, Parisi C, Pawankar R, Piñero-Saavedra M, Popov TA, Porebski G, Prieto Garcia A, Pyatilova P, Rudenko M, Sekerel BE, Serpa FS, Sheikh F, Siebenhaar F, Soria A, Staevska M, Staubach P, Stobiecki M, Thomsen SF, Triggiani M, Valerieva A, Valle S, Van Dinh N, Vera Ayala CE, Zalewska-Janowska A, Zanichelli A, Magerl M, and Maurer M

Subjects
Humans, Abbreviations as Topic, Delphi Technique, Angioedema classification, Angioedema diagnosis, Consensus, Terminology as Topic
Abstract

Background: Angioedema (AE) manifests with intermittent, localized, self-limiting swelling of the subcutaneous and/or submucosal tissue. AE is heterogeneous, can be hereditary or acquired, may occur only once or be recurrent, may exhibit wheals or not, and may be due to mast cell mediators, bradykinin, or other mechanisms. Several different taxonomic systems are currently used, making it difficult to compare the results of studies, develop multicenter collaboration, and harmonize AE treatment., Objective: We developed a consensus on the definition, acronyms, nomenclature, and classification of AE (DANCE)., Methods: The initiative involved 91 experts from 35 countries and was endorsed by 53 scientific and medical societies, and patient organizations. A consensus was reached by online discussion and voting using the Delphi process over a period of 16 months (June 2021 to November 2022)., Results: The DANCE initiative resulted in an international consensus on the definition, classification, and terminology of AE. The new consensus classification features 5 types and endotypes of AE and a harmonized vocabulary of abbreviations/acronyms., Conclusion: The DANCE classification complements current clinical guidelines and expert consensus recommendations on the diagnostic assessment and treatment of AE. DANCE does not replace current clinical guidelines, and expert consensus algorithms and should not be misconstrued in a way that affects reimbursement of medicines prescribed by physicians using sound clinical judgment. We anticipate that this new AE taxonomy and nomenclature will harmonize and facilitate AE research and clinical studies, thereby improving patient care., (Copyright © 2024. Published by Elsevier Inc.)

Published
2024
Full Text
View/download PDF

49. Usage prevalence of angioedema patient-reported outcome measures: Results from the UCARE and ACARE PROMUSE study.

Author

Cherrez-Ojeda I, Bousquet J, Giménez-Arnau A, Godse K, Krasowska D, Bartosińska J, Szczepanik-Kułak P, Wawrzycki B, Kolkhir P, Allenova A, Allenov A, Tkachenko S, Mitrevska NT, Mijakoski D, Stoleski S, Kolacinska-Flont M, Kuprys-Lipinska I, Molinska J, Kasperska-Zając A, Zajac M, Zamłyński M, Mihaltan F, Ulmeanu R, Zalewska-Janowska A, Tomaszewska K, Al-Ahmad M, Al-Nesf MA, Ibrahim T, Aqel S, Pesqué D, Rodríguez-González M, Wakida-Kuzunoki GH, Ramon GD, Ramon GN, Neisinger S, Bonnekoh H, Rukhadze M, Khoshkhui M, Fomina D, Larenas-Linnemann D, Košnik M, Kara RO, Caballero López CG, Liu Q, Ivancevich JC, Ensina LF, Rosario N, Kvedariene V, Ben-Shoshan M, Jardim Criado RF, Bauer A, Cherrez A, Cherrez S, Chong-Neto H, Rojo-Gutierrez MI, Rudenko M, Larco Sousa JI, Lesiak A, Matos E, Tinoco I, Shijin CC, Logroño RH, Sagñay JC, Faytong-Haro M, Robles-Velasco K, Zuberbier T, and Maurer M

Subjects
Humans, Female, Male, Adult, Prevalence, Middle Aged, Surveys and Questionnaires, Patient Reported Outcome Measures, Angioedema epidemiology
Published
2024
Full Text
View/download PDF

50. Non-Skin Related Symptoms Are Common in Chronic Spontaneous Urticaria and Linked to Active and Uncontrolled Disease: Results From the Chronic Urticaria Registry.

Author

Pyatilova P, Hackler Y, Aulenbacher F, Asero R, Bauer A, Bizjak M, Day C, Dissemond J, Du-Thanh A, Fomina D, Giménez-Arnau AM, Grattan C, Gregoriou S, Hawro T, Kasperska-Zajac A, Khoshkhui M, Kocatürk E, Kovalkova E, Kulthanan K, Kuznetsova E, Makris M, Mukhina O, Pesqué D, Peter J, Salameh P, Siebenhaar F, Sikora A, Staubach P, Tuchinda P, Zamłyński M, Weller K, Maurer M, and Kolkhir P

Subjects
Humans, Female, Male, Adult, Middle Aged, Fever epidemiology, Adolescent, Young Adult, Quality of Life, Aged, Arthralgia epidemiology, Urticaria epidemiology, Registries, Chronic Urticaria epidemiology
Abstract

Background: Chronic spontaneous urticaria (CSU) can present with non-skin related symptoms (NSRS), including recurrent unexplained fever, joint, bone, or muscle pain (JBMP), and malaise, which also occur in other conditions that manifest with wheals (eg, urticarial vasculitis or autoinflammatory disorders) or without wheals (eg, infection)., Objective: We sought to determine the rate of patients with CSU affected by fever, JBMP, and malaise, their trigger factors, links with clinical and laboratory characteristics, and their impact on everyday life and treatment responses., Methods: We analyzed baseline data from the Chronic Urticaria Registry of 2,521 patients with CSU who were aged 16 years or older., Results: One third of CSU patients (31.2%; 786 of 2,521) had one or more NSRS, including recurrent fever (5.3%), JBMP (19.1%), and/or malaise (18.6%). In a multivariable analysis, having one or more of these NSRS correlated with food and infection as trigger factors of urticaria (adjusted odds ratio [aOR] = 1.7 and 1.5), wheals of 24 hours or greater duration (aOR = 2.5), sleep disturbance (aOR = 2.4), anxiety (aOR = 2.8), comorbid atopic dermatitis (aOR = 2.1), gastrointestinal disease (aOR = 1.8), elevated leukocytes (aOR = 1.7) and erythrocyte sedimentation rate (aOR = 1.5). In a bivariate analysis, these NSRS were additionally associated with higher disease activity (weekly Urticaria Activity Score, median: 21 vs 14; P = .009), longer disease duration (years, median: 2 vs 1; P = .001), the presence of angioedema (74.6% vs 58.7%; P < .001), worse quality of life (Chronic Urticaria Quality of Life Questionnaire, median: 42 vs 29; P < .001) and more frequent poor control of CSU (78% vs 69%; P < .001)., Conclusions: The presence of NSRS in a subpopulation of patients with CSU points to the need for better control of the disease, exclusion of comorbid conditions, and/or exclusion of urticarial vasculitis and urticarial autoinflammatory diseases., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results